<DOC>
	<DOCNO>NCT00282139</DOCNO>
	<brief_summary>This open-label , flexible dose study design evaluate safety efficacy aripiprazole TS ( chronic tic disorder ) subject without associate OC symptom without ADHD symptom .</brief_summary>
	<brief_title>Aripiprazole Treatment Tourette 's Syndrome</brief_title>
	<detailed_description>This open-label , flexible dose study design evaluate safety efficacy aripiprazole TS ( chronic tic disorder ) subject without associate OC symptom without ADHD symptom .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>DSMIV primary diagnosis Tourette 's syndrome chronic tic disorder ; `` Moderate '' severity reflect CGI YGTSS ; Normal ECG ; , Written inform consent/assent . Female subject childbearing potential practicing effective method birth control ( include abstinence ) ; Subjects pregnant nursing woman ; Subjects know seizure disorder , history seizure condition low seizure threshold ; Subjects currently meet DSMIV criterion : Schizophrenia , Schizoaffective Disorder , Delusional Disorder , Psychotic Disorder Not Otherwise Specified ; Subjects Psychoactive Substance Abuse disorder ( within past 3 month ) ; Subjects know allergy hypersensitivity aripiprazole ; Subjects depot neuroleptic within one treatment cycle change psychoactive medication ( exception antidepressant ) one month two month antidepressant prior study entry first administration study medication ; Subjects clinically significant abnormality base physical examination , medical history , ECG , laboratory test ; , Subjects medication pose drug interaction potential aripiprazole carbamazepine , ketoconazole , paroxetine , fluoxetine .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>